[1] 项波,白明辉,胡永珍,等.慢性乙型肝炎患者医院感染的临床相关因素分析. 中华医院感染学杂志. 2016,26(24):5578-5580. [2] Bard-Chapeau EA,Nguyen AT,Rust AG,et al.Transposon mutagenesis identifies genes driving hepatocellular carcinoma in a chronic hepatitis B mouse model. Nat Genet,2014,46(1):24-32. [3] 史萍,蒋龙凤,李军,等. 慢性乙型肝炎患者核苷(酸)类药物停药后复发的相关因素荟萃分析. 中华临床感染病杂志,2015,8(1):58-69. [4] Liu CJ,Kao JH.Global perspective on the natural history of chronic hepatitis B:role of hepatitis B virus genotypes A to [J]. Semin Liver Dis,2013,33(2):97-102. [5] Younossi ZM,Stepanova M,Chan HL,et al.Patient reported outcomes in Asian patients with chronic hepatitis C treated with ledipasvir and sofosbuvir. Medicine(Baltimore),2016,95(9):e2702. [6] Lai CL,Wong VW,Yuen MF,et al.Sofosbuvir plus ribavirin for the teratment of patients with chronic genotype 1 or 6 hepatitis C virus infection in Hong Kong. Aliment Pharmacol Ther,2016,43(1):96-101. [7] Goyal SK,Jain AK,Dixit VK,et al.HBsAg level as predictor of liver fibrosis in HBeAg positive patients with chronic hepatitis B virus infection. J Clin Exp Hepatol,2015,5(3):213-220. [8] McMahon BJ,Bulkow L,Simons B,et al. Relationship between level of HBV DNA and liver disease-a population-based study of hepatitits B e antigen-negative persons with hepatitis B. Clin Gastroenterol Hepatol,2014,12(4):701-706. [9] 吴泽倩,谭雷,刘婷,等. HBeAg阴性慢性乙型肝炎患者血清HBsAg水平在不同肝组织炎症分级和纤维化分期的变化. 中华肝脏病杂志,2014,22(12):895-899. [10] Seto WK,Lai CL,Ip PP,et al.A large population histology study showing the lack of association between ALT elevation and significant fibrosis in chronic hepatitis B. PLos One,2012,7(2):e32622. [11] 陆伟,张占卿,沈芳,等. 血清HBsAg 和HBV DNA 定量水平预测慢性乙型肝炎患者肝组织炎症活动度和纤维化程度的评价. 实用肝脏病杂志,2016,19(1):20-25. [12] Petta S,Vanni E,Bugianesi E,et al.The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasi ve diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease. Liver Int,2015,35(5):1566-1573. [13] Teshale E,Lu M,Rupp L B,et al.APRI and FIB-4 are good predictors of the stage of liver fibrosis in chronic hepatitis B:the Chronic Hepatitis Cohort Study (CheCS). J Viral Hepat,2014,21(12):917-920. [14] Angulo P,George J,Day C P,et al.Serum ferritin levels lack diagnostic accuracy for liver fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol,2014,12(7):1163-1169. [15] Wan R,Liu H,Wang X,et al.Noninvasive predictive models of liver fibrosis in patients with chronic hepatitis B. Int J Clin Exp Med,2015,8(1):961-971. [16] Zeng X,Xu C,He D,et al.Performance of several simple, noninvasive models for assessing significant liver fibrosis in patients with chronic hepatitis B. Croat Med J,2015,56(3):272-279. [17] Wrotkowska M,Stalke P,Smiatacz T,et al.Hematological complications in chronic hepatitis C virus infection. Blood,2014,124(21):2169-2169. [18] Gao S,Li XY,Fan YC,et al.A noninvasive model to predict liver histology in HBeAg-positive chronic hepatitis B with alanine aminotransferas≤2 upper limit of normal. J Gastroenterol Hepatol,2017,32(1):215-220. [19] Jia W,Qi X,Ji YY,et al.Low serum hepatitis B surface antigen level predicts compensated cirrhosis caused by chronic hepatitis B in HBeAg positive patients in east China. Hepat Mon,2015,15(8):e29183. [20] Zhang ZQ,Lu W,Wang YB,et al.Measurement of the hepatitis B core-related antigen is valuable for predicting the pathological status of liver tissues in chronic hepatitis B patients. J Virol Methods,2016,235:92-98. |